Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03921996
Recruitment Status : Not yet recruiting
First Posted : April 19, 2019
Last Update Posted : April 19, 2019
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

Brief Summary:
For patients with intermediate-risk prostate cancer plus a predicted risk of >5% for positive lymph nodes and with high-risk prostate cancer, international guidelines recommend ePLND along with the RP. Besides an improved accuracy in staging, the therapeutic role of ePLND remains controversial. We hypothesize that ePLND prolongs time to biochemical recurrence (BCR) and prostate cancer-specific survival (PCSS) in intermediate- and high-risk PCa patients.

Condition or disease Intervention/treatment Phase
Prostate Cancer Procedure: Radical prostatectomy (RP) followed by ePLND Procedure: Radical prostatectomy (RP) only Phase 3

Detailed Description:

Radical prostatectomy (RP) is the surgical standard treatment for men with localized prostate cancer (PCa) and a life expectancy of > 10 years. RP is a treatment option for localized PCa that shows benefit in prostate cancer-specific survival (PCSS) and overall survival compared to conservative management. According to the guideline recommendations of the European Association of Urology (EAU), RP should be accompanied by extended pelvic lymph node dissection (ePLND) in patients with intermediate-risk PCa (D'Amico classification) and > 5% nomogram (Briganti) predicted risk of positive lymph nodes and in all high-risk PCa cases.

Besides an improved accuracy in staging, the therapeutic role of ePLND remains controversial. The primary goal of this trial is to provide high-level evidence regarding the therapeutic benefit of ePLND in intermediate- and high-risk PCa patients without clinical evidence of nodal involvement. It is hypothesized that ePLND prolongs time to biochemical recurrence (BCR) and prostate cancer-specific survival (PCSS) in intermediate- and high-risk PCa patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 900 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: SAKK 09/18 is an international, multicenter, randomized, phase III surgical intervention trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer: An International, Multicenter, Randomized Phase III Trial
Estimated Study Start Date : July 1, 2019
Estimated Primary Completion Date : September 30, 2023
Estimated Study Completion Date : December 31, 2038

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: arm A: ePLND
Radical prostatectomy with extended pelvic lymph node dissection
Procedure: Radical prostatectomy (RP) followed by ePLND
ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue

Active Comparator: arm B: no PLND
Radical prostatectomy only
Procedure: Radical prostatectomy (RP) only
Radical prostatectomy




Primary Outcome Measures :
  1. Time to biochemical recurrence (BCR) [ Time Frame: From the date of randomization until the date of biochemical recurrence, assessed up to 15 years after surgery ]
    The primary endpoint of this trial is time to BCR, defined as time from randomization to biochemical recurrence, defined as serum PSA level ≥ 0.2 ng/ml, with a second confirmatory serum PSA level ≥ 0.2 ng/ml. Patients not experiencing an event will be censored at the date of the last available assessment or at the start of adjuvant or salvage treatment, if any.


Secondary Outcome Measures :
  1. Prostate-specific antigen (PSA) persistence [ Time Frame: From the date of surgery to 14 weeks after surgery ]

    PSA persistence is defined as failure to reach a PSA value of <0.1 ng/ml within 12 weeks (+ 2 weeks) postoperatively.

    Patients with no assessments within the first 12 weeks (+ 2 weeks) after surgery will be counted as failures for this endpoint


  2. Time to initiation of adjuvant or salvage therapies [ Time Frame: From the date of randomization until the date of start of any type of adjuvant or salvage therapy, assessed up to 15 years after surgery ]
    Time to initiation of adjuvant or salvage therapies will be calculated as the time from randomization to the start of any type of adjuvant or salvage therapy. Patients not starting adjuvant or salvage therapies are censored at the last date they were known to be alive.

  3. Time to loco-regional recurrence [ Time Frame: From the date of randomization until the date of local or regional recurrence, assessed up to 15 years after surgery ]
    Time to loco-regional recurrence will be calculated from randomization until local (prostate bed) or regional (extent of ePLND template) recurrence, whichever occurs first. Patients not experiencing an event will be censored at the date of the last available assessment or at the start of adjuvant or salvage therapy, if any.

  4. Time to distant metastasis [ Time Frame: From the date of randomization until the date of first occurrence of distant metastasis, assessed up to 15 years after surgery ]
    Time to distant metastasis will be calculated from randomization until first occurrence of distant metastasis. Patients not experiencing an event will be censored at the date of the last available assessment.

  5. Prostate cancer-specific survival (PCSS) [ Time Frame: From the date of randomization until the date of death due to prostate cancer, assessed up to 15 years after surgery ]

    PCSS will be calculated as the time from randomization to the date of death due to prostate cancer. Patients who died due to other reasons will be censored at the time of death. All other patients will be censored at the last date they were known to be alive.

    Causes of death may require critical review by the coordinating investigator and the medical advisor. Particular attention will be paid to men who have been reported as having died from prostate cancer without previously reported progression or recurrence and men who were reported as having died from non-prostate cancer causes after developing biochemical or clinical progression.


  6. Overall survival (OS) [ Time Frame: From the date of randomization until the date of death, assessed up to 15 years after surgery ]
    OS will be calculated from randomization until death from any cause. Patients not experiencing an event will be censored at the last date they were known to be alive.

  7. Intraoperative complications [ Time Frame: During surgery ]
    Intraoperative complications will be assessed using the CLASSIC system.

  8. Postoperative complications [ Time Frame: From the date of surgery to 14 weeks after surgery ]
    Postoperative complications will be assessed using the Clavien-Dindo classification.

  9. Adverse events (AE) [ Time Frame: From the date of registration to 15 years after surgery ]
    AEs will be assessed according to NCI CTCAE v5.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures.
  • Histologically proven localized adenocarcinoma of the prostate.
  • High-risk prostate cancer or intermediate-risk prostate cancer defined by D'Amico classification system, with an estimated risk of >5% of lymph node metastasis.
  • Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence.
  • Age ≥ 18 years and ≤ 80 years.
  • WHO performance status 0-1.
  • Adequate condition (ASA ≤ III) for general anesthesia and radical prostatectomy surgery.
  • Baseline Quality of Life (QoL) questionnaires have been completed.

Exclusion criteria

  • Any pre-operative evidence for T4 disease.
  • Metastatic prostate cancer according to staging or evidence of lymph node metastasis by imaging, defined as any pelvic lymph node >9 mm in the short axis or positive lymph nodes detected by imaging techniques with sensitivities similar or better than PSMA-PET or Choline-PET prior to surgery.
  • PSA ≥ 50 ng/ml.
  • Any prior neo-adjuvant, local or systemic treatment for prostate cancer (alpha reductase inhibitors for treatment of benign hyperplasia are allowed)
  • Previous pelvic lymph node dissection.
  • Any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment.
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03921996


Contacts
Layout table for location contacts
Contact: Corinne Schär, PhD +41 31 389 91 91 trials@sakk.ch

Locations
Layout table for location information
Switzerland
Kantonsspital Aarau AG Not yet recruiting
Aarau, Switzerland, 5001
Contact: Maciej Kwiatkowski, Prof    +41 62 838 47 47    maciej.kwiatkowski@ksa.ch   
Principal Investigator: Maciej Kwiatkowski, Prof         
Universitätsspital Basel Not yet recruiting
Basel, Switzerland, 4031
Contact: Helge Seifert, Prof    +41 61 328 72 84    helge.seifert@usb.ch   
Principal Investigator: Helge Seifert, Prof         
Inselspital, Bern Not yet recruiting
Bern, Switzerland, 3010
Contact: George N. Thalmann, Prof    +41 31 632 36 64    george.thalmann@insel.ch   
Principal Investigator: Geroge Thalmann, Prof         
Kantonsspital Graubuenden Not yet recruiting
Chur, Switzerland, 7000
Contact: Räto Strebel, MD    +41 81 256 62 37    raeto.strebel@ksgr.ch   
Principal Investigator: Räto Strebel, MD         
Kantonsspital Frauenfeld Not yet recruiting
Frauenfeld, Switzerland, 8501
Contact: Thomas R. Herrmann, Prof    +41 52 723 7674    thomas.herrmann@stgag.ch   
Principal Investigator: Thomas R. Herrmann, Prof         
Kantonsspital Baselland Not yet recruiting
Liestal, Switzerland, 4410
Contact: Svetozar Subotic, MD    +41 61 925 21 72    svetozar.subotic@ksbl.ch   
Principal Investigator: Svetozar Subotic, MD         
Stadtspital Triemli Not yet recruiting
Zürich, Switzerland, 8063
Contact: Michael Müntener, MD    +41 44 466 27 02    michael.muentener@triemli.zuerich.ch   
Principal Investigator: Michael Müntener, MD         
Universitätsspital Zürich Not yet recruiting
Zürich, Switzerland, 8091
Contact: Cédric Poyet, MD    +41 44 255 54 40    cedric.poyet@usz.ch   
Principal Investigator: Cédric Poyet, MD         
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Investigators
Layout table for investigator information
Study Chair: Cyrill A. Rentsch, MD-PhD University Hospital Basel, Department of Urology

Layout table for additonal information
Responsible Party: Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier: NCT03921996     History of Changes
Other Study ID Numbers: SAKK 09/18
First Posted: April 19, 2019    Key Record Dates
Last Update Posted: April 19, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Swiss Group for Clinical Cancer Research:
Extended pelvic lymph node dissection
Pelvic lymph node dissection
ePLND
Prostate Cancer
intermediate prostate cancer
High-risk prostate cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases